What is Omeros?
Founded in 1994, Omeros operates at the intersection of biotechnology and advanced medicine. The company is dedicated to the discovery and development of therapeutics for both large-market indications and orphan diseases. Its research focus is primarily centered on the underlying mechanisms of inflammation and coagulopathies, areas where the company has established a significant intellectual property portfolio. By leveraging its expertise in protein and small-molecule chemistry, Omeros aims to address unmet medical needs, positioning itself as a critical player in the biopharmaceutical landscape. The company's long-term strategy involves transitioning from a research-heavy entity to a commercial-stage organization, supported by a history of consistent funding and strategic partnerships.
How much funding has Omeros raised?
Omeros has raised a total of $1.1B across 22 funding rounds:
Stock Offering
$84M
Multiple Rounds
$215M
Stock Offering
$63.6M
Debt
$210M
Stock Offering
$57.5M
Debt
$92.1M
Other Financing Round
$4M
Stock Issuance/Offering (2015): $84M, investors not publicly disclosed
Debt (2016): $50M backed by Oxford Finance and East West Bank
Stock Issuance/Offering (2016): $40M with participation from Cantor Fitzgerald & Co.
Debt (2016): $125M led by CRG LP
Stock Issuance/Offering (2017): $63.6M, investors not publicly disclosed
Debt (2018): $210M, investors not publicly disclosed
Stock Issuance/Offering (2019): $57.5M, investors not publicly disclosed
Debt (2024): $92.1M with participation from Athyrium Capital Management and Highbridge Capital Management
Other Financing Round (2025): $4M led by National Institute on Drug Abuse
Key Investors in Omeros
CRG LP
CR Group L.P. is a global investment firm focused on enhancing healthcare through flexible growth capital solutions, specializing in credit and equity investments across life sciences.
Athyrium Capital Management
Athyrium Capital Management is a leading investment platform focused on structured investments in the global healthcare sector, including royalties and structured credit.
RA Capital Management
RA Capital Management is a multi-stage investment manager focused on evidence-based investing in public and private healthcare and life science companies.
What's next for Omeros?
Looking ahead, the recent capital injection provides Omeros with the necessary runway to accelerate its late-stage clinical trials and prepare for potential commercial launches. The company's focus will likely remain on optimizing its therapeutic pipeline while managing the complexities of the regulatory environment. With a history of securing both equity and debt financing, Omeros has demonstrated a sophisticated approach to capital structure management. Future growth will depend on the successful translation of its scientific research into market-ready products, supported by the continued backing of its institutional partners who specialize in life sciences and healthcare innovation.
See full Omeros company page
